Rhabdomyosarcoma Treatment and Outcome at a Multidisciplinary Pediatric Cancer Center in Lebanon

REFERENCES

• Meyer WH, Spunt SL. Soft tissue sarcomas of childhood. Cancer Treat Rev. 2004;30(3):269–280.
   Google Scholar
• Raney RB, Maurer HM, Anderson JR, The Intergroup Rhabdomyosarcoma Study Group (IRSG): major lessons from the IRS-I through IRS-IV studies as background for the current IRS-V treatment protocols. Sarcoma. 2001;5(1):9–15.
   PubMedGoogle Scholar
• Spunt SL, Smith LM, Ruymann FB, Cyclophosphamide dose intensification during induction therapy for intermediate-risk pediatric rhabdomyosarcoma is feasible but does not improve outcome: a report from the soft tissue sarcoma committee of the children's oncology group. Clin Cancer Res. 2004;10(18 Pt 1):6072–6079.
   PubMed Web of Science ®Google Scholar
• Arndt CA, Stoner JA, Hawkins DS, Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803. J Clin Oncol. 2009;27(31):5182–5188.
   PubMed Web of Science ®Google Scholar
• Crist WM, Anderson JR, Meza JL, Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. J Clin Oncol. 2001;19(12):3091–3102.
   PubMed Web of Science ®Google Scholar
• Rodeberg D, Arndt C, Breneman J, Characteristics and outcomes of rhabdomyosarcoma patients with isolated lung metastases from IRS-IV. J Pediatr Surg. 2005;40(1):256–262.
   Google Scholar
• Huh WW, Skapek SX. Childhood rhabdomyosarcoma: new insight on biology and treatment. Curr Oncol Rep. 2010;12(6):402–410.
   PubMed Web of Science ®Google Scholar
• Oberlin O, Rey A, Lyden E, Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. J Clin Oncol. 2008;26(14):2384–2389.
   PubMed Web of Science ®Google Scholar
• Antillon F, Castellanos M, Valverde P, Treating pediatric soft tissue sarcomas in a country with limited resources: the experience of the Unidad Nacional de Oncologia Pediatrica in Guatemala. Pediatr Blood Cancer. 2008;51(6):760–764.
   Google Scholar
• Hessissen L, Kanouni L, Kili A, Pediatric rhabdomyosarcoma in Morocco. Pediatr Blood Cancer. 2010;54(1):25–28.
   Google Scholar
• Shouman T, El-Kest I, Zaza K, Rhabdomyosarcoma in childhood: a retrospective analysis of 190 patients treated at a single institution. J Egypt Natl Canc Inst. 2005;17(2):67–75.
   Google Scholar
• Park JA, Kim EK, Kang HJ, Initial response to treatment was highly associated with the prognosis of childhood rhabdomyosarcoma: a retrospective analysis of a single center experience in Korea. Cancer Res Treat. 2008;40(3):111–115.
   Google Scholar
• Hosoi H, Teramukai S, Matsumoto Y, A review of 331 rhabdomyosarcoma cases in patients treated between 1991 and 2002 in Japan. Int J Clin Oncol. 2007;12(2):137–145.
   Google Scholar
• Yuan XJ, Chan GC, Chan SK, Treatment outcome of rhabdomyosarcoma in Hong Kong Chinese children. Hong Kong Med J. 2008;14(2):116–123.
   Google Scholar
• Baker KS, Anderson JR, Link MP, Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma: results from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol. 2000;18(12):2427–2434.
   PubMed Web of Science ®Google Scholar
• Breneman JC, Lyden E, Pappo AS, Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma—a report from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol. 2003;21(1):78–84.
   PubMed Web of Science ®Google Scholar
• Squatrito M, Brennan CW, Helmy K, Loss of ATM/Chk2/p53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas. Cancer Cell. 2010;18(6):619–629.
   PubMed Web of Science ®Google Scholar
• Jeggo P, Lavin MF. Cellular radiosensitivity: how much better do we understand it? Int J Radiat Biol. 2009;85(12):1061–1081.
   PubMed Web of Science ®Google Scholar
• Lu C, El-Deiry WS. Targeting p53 for enhanced radio- and chemo-sensitivity. Apoptosis. 2009;14(4):597–606.
   PubMed Web of Science ®Google Scholar
• Kim ST, Lim DS, Canman CE, Substrate specificities and identification of putative substrates of ATM kinase family members. J Biol Chem. 1999;274(53):37538–37543.
   PubMed Web of Science ®Google Scholar
• O'Neill T, Dwyer AJ, Ziv Y, Utilization of oriented peptide libraries to identify substrate motifs selected by ATM. J Biol Chem. 2000;275(30):22719–22727.
   PubMed Web of Science ®Google Scholar
• Dagher R, Helman L. Rhabdomyosarcoma: an overview. Oncologist. 1999;4(1):34–44.
   PubMedGoogle Scholar
• Sultan I, Qaddoumi I, Yaser S, Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: an analysis of 2,600 patients. J Clin Oncol. 2009;27(20):3391–3397.
   Web of Science ®Google Scholar
• Baker KS, Anderson JR, Lobe TE, Children from ethnic minorities have benefited equally as other children from contemporary therapy for rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study Group. J Clin Oncol. 2002;20(22):4428–4433.
   Google Scholar
• Bhatia S. Disparities in cancer outcomes: lessons learned from children with cancer. Pediatr Blood Cancer. 2011;56(6):994–1002.
   PubMed Web of Science ®Google Scholar
• Grabenbauer GG, Mühlfriedel C, Rödel F, Squamous cell carcinoma of the oropharynx: Ki-67 and p53 can identify patients at high risk for local recurrence after surgery and postoperative radiotherapy. Int J Radiat Oncol Biol Phys. 2000;48(4):1041–1050.
   Google Scholar
• Minn AY, Lyden ER, Anderson JR, Early treatment failure in intermediate-risk rhabdomyosarcoma: results from IRS-IV and D9803—a report from the Children's Oncology Group. J Clin Oncol. 2010;28(27):4228–4232.
   Google Scholar
• Phan VH, Moore MM, McLachlan AJ, Ethnic differences in drug metabolism and toxicity from chemotherapy. Expert Opin Drug Metab Toxicol. 2009;5(3):243–257.
   PubMed Web of Science ®Google Scholar